1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
Martin Reck, Alexander I. Spira, Benjamin Besse, Jennifer Moriatis Wolf, Ferdinandos Skoulidis, Hossein Borghaei, Kōichi Goto, K. Park, Frank Griesinger, Enriqueta Felip, Michael Boyer, Carlos H. Barrios, Glenwood Goss, Hui Yang, Cynthia Obiozor, Suresh S. Ramalingam
Topics & Concepts
KRASDocetaxelMedicineClinical endpointOncologyInternal medicinePhases of clinical researchProgression-free survivalExpanded accessCancerChemotherapyResponse Evaluation Criteria in Solid TumorsProgressive diseaseClinical trialColorectal cancerLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerCancer therapeutics and mechanisms